Discussing RA: July 2024




Join Professor Iain McInnes and guest Professor Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.

In this episode, two papers that cover important topics in rheumatology are highlighted: the first paper presents the 5-year efficacy and safety results of upadacitinib in RA, while the second provides an overview of the literature and guidance on discussing outcomes regarding children born of mothers with autoimmune rheumatic diseases.

June 2024

AxSpA Podcast: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status




Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by baseline MRI and CRP status.

Discussing RA: June 2024




Join Professors Iain McInnes, Peter Nash, and Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.

In this episode they discuss two papers, one that investigated the long-term safety of filgotinib in moderate-to-severe RA, and the other a postmarketing analysis of adverse cardiovascular events with JAKi treatments in RA.

May 2024

Discussing RA: May 2024




Join Professor Iain McInnes and guests Professor Janet Pope and Dr Sofia Ramiro for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers that investigated the long-term safety of JAK inhibitors from Phase 3 trials. In our first paper, Maya Buch and colleagues examined extended MACE endpoints with tofacitinib versus TNFi. Our second paper is from Gerd Burmester and colleagues present long-term efficacy and safety data for upadacitinib through five years. To access detailed summary slides for the papers discussed today, visit imidforum.com.

PsA Podcast: Bimekizumab therapy in PsA




Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the latest publication by Su, et al. and discuss the latest in bimekizumab therapy in PsA.

IMID Author Interview: Dr Blanca Hernández-Cruz, 2024




Join Professor Peter Nash from the Griffith University in Brisbane, and Blanca Hernández-Cruz, a rheumatologist at Virgen Macarena University Hospital in Seville, as they discuss her recent paper ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry’.